The ambition for IBP-9414 is to become the world’s first approved pharmaceutical grade probiotic drug to prevent life threatening infant diseases including NEC, by promoting healthy stomach- and bowel development in premature infants.
The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications are pending in additional important future markets including the US and
The patent provides coverage until 2036. IBP-9414 is intended to be marketed in
“We are very pleased that IBT has succeeded in expanding our intellectual property protection for IBP-9414 through the approved patent in an important additional market” says Staffan Strömberg, Chief Executive Officer of IBT.
About
IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
For additional information please contact
Staffan Strömberg, CEO
Bryggargatan 10
111 21 Stockholm
Telefon: +46 8 410 145 55
info@ibtherapeutics.com
www.ibtherapeutics.com
Publication
This information is information that
Attachment
- PR 10Jan2022 AUS
IP ENG
© OMX, source